Masking MALT1: the paracaspase's potential for cancer therapy.
A key feature of aggressive B cell lymphomas is constitutive NF-kappaB activation, which requires signals from the CARD11-BCL-10-MALT1 (CMB) complex. The unique enzymatic activity of MALT1 degrades one of its binding partners, BCL-10, as well as the NF-kappaB inhibitor A20. New data shows that targeting MALT1 protease activity may be a promising therapeutic strategy for treating aggressive B cell lymphomas.
Vucic
Domagoj
D
Department of Protein Engineering, Genentech, Inc., South San Francisco, CA 94080, USA. vucic.domagoj@gene.com
Dixit
Vishva M
VM
D000818:Animals; D061945:Caspase Inhibitors; D020169:Caspases / Q000737:chemistry / Q000378:metabolism*; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D016393:Lymphoma, B-Cell / Q000201:enzymology* / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D011480:Protease Inhibitors / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects
D061945:Caspase Inhibitors; D011480:Protease Inhibitors; D020169:Caspases